VEGFA and neoplasm: In experimental tumour settings where anti-angiogenic drugs, including TKIs or anti-VEGF antibodies, demonstrated efficacy, a notable outcome emerged: there was a discernible reduction in the expression of immune checkpoints on the surface of T cells.